Federico II University of Naples
Naples, 80131, Italy
NCT Number: NCT01124942
The Investigators will test the hypothesis that MGuard net protective stent, the investigational device, would be superior to conventional revascularization strategy (i.e. bare-metal stenting plus manual thrombectomy), for STEMI patients undergoing urgent percutaneous coronary interventions.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Naples, 80131, Italy
Embolization of thrombotic debris still represents a complication for ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary interventions (PCI).
Distal embolization may decrease coronary and myocardial reperfusion after PCI in STEMI setting.
Unfortunately, intracoronary filters present several important limitations limiting their use and their efficacy especially in presence of huge amount of thrombus. In this respect, recent trials investigated whether a default manual thrombectomy strategy before stenting would ameliorate angiographic as well as clinical outcomes for STEMI patients undergoing percutaneous revascularization.
Of note, the most of embolization occurs when guidewire, and thrombectomy device cross the thrombus, and after the stent has been implanted as a consequence of plaque prolapse through the stent struts.
MGuard net protective stent, the investigational device, is a bare-metal stent covered with a ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, that is anchored to the external surface of the struts. This biocompatible fiber net (string diameter 10-22 μm) has minimal effects on the stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net and isolating the prothrombotic intima components from the blood stream.
This protocol will test the hypothesis that MGuard stent would be superior to conventional revascularization strategy (i.e. bare-metal stenting plus manual thrombectomy), for STEMI patients undergoing urgent PCI in terms of angiographic as well as clinical outcomes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.
Other names: MGuard net protective stent
Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent
Time frame: 30 minutes after revascularization
Myocardial Perfusional Blush Grade 2-3 at the end of the procedure
Time frame: 1 month
Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.
Time frame: 60 minutes after revascularization
Complete (>70%) ST-segment resolution at 60 minutes post-revascularization
Time frame: 30 minutes after revascularization
TIMI coronary flow at the end of the procedure
Time frame: 30 minutes after revascularization
Corrected TIMI Frame count at the end of the procedure
Time frame: 6 months
Six-month infarct related area reduction and left ventricular ejection fraction recovery as compared with infarct related area and and left ventricular ejection fraction at admission.
Time frame: 60 minutes after revascularizationl
Device performance evaluated during the procedure in terms of pushability, trackability, crossability and deliverability
Time frame: 6 months
Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.
Time frame: 12 months
Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.
Federico II University
Other
MGuard vs bAre-metal Stents Plus Manual Thrombectomy in Real World STEMI Patients: a Prospective Multicenter Randomized Trial
Acronym: GUARDIAN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04927949
Cardiovascular Diseases, Heart Diseases
Caen, France
View Trial DetailsNCT01197729
Cardiovascular Diseases, Heart Diseases
Münster, Germany
View Trial DetailsNCT01717573
Cardiovascular Diseases, Heart Diseases
Clydebank, Glasgow, United Kingdom
View Trial DetailsNCT06426537
Cardiovascular Diseases, Heart Diseases
Tulungagung, East Java, Indonesia
View Trial Details